Analysis
The future of US-China business relations under Trump vs. Biden
US-China relations are clearly on the ballot in the upcoming US election – but how will the outcome impact US foreign and economic policy toward countries like China.
Kiersten Archer
Director
Kiersten Archer is a Director within Controls Risks’ Compliance, Forensics and Intelligence practice in the Americas region. She has significant experience in corporate compliance, fraud and anti-corruption matters.
- Americas
- Corruption Risk Assessment & Analysis
- Cross Border Investigations
- Government-Mandated Monitorships
Kiersten Archer is a Director within Controls Risks’ Compliance, Forensics and Intelligence practice in the Americas region. She has significant experience in corporate compliance, fraud and anti-corruption matters.
Kiersten specializes in bribery and fraud investigations, compliance risk assessments and development of best-practice anti-corruption compliance programs. Her experience in matters involving violations of the US Foreign Corrupt Practices Act (FCPA) and the UK Bribery Act includes global financial and forensic accounting investigations with suspected violations by US corporations or their international operating divisions, agents or distributors. She has also worked on global risk assessments, SEC and DOJ enforcement-driven investigations, and monitorships in numerous global jurisdictions.
In 2019, Control Risks’ Regulatory Risks and Investigations Team in the Americas, which Kiersten is a part of, was named Compliance Consulting Team of the Year at the C5 Women in Compliance Awards.
Kiersten’s recent experience includes:
- Participation in global on-site anti-corruption investigations and risk assessments for medical devices, pharmaceutical and dental implant companies, including focused transactional testing and data analytics to determine FCPA corruption risk.
- Assisted clients with global compliance program gap analyses and remediation, including development of corruption risk profiles.
- In a large financial institution securities litigation matter, assisted in responding to allegations that senior management issued materially false and misleading financial reports, artificially inflating the price of the entity’s securities.
- Participated in a complex independent investigation into a leading pharmaceutical company’s operations and interactions with healthcare professionals, distributors and vendors in China.Played a key role on a court-appointed independent compliance consulting team for a large global pharmaceutical company in connection with an FCPA settlement with the SEC.
Prior to joining Control Risks, Kiersten spent a decade at FTI Consulting where she was a senior director in its forensic and litigation consulting practice focusing on anti-corruption compliance and investigations.
Related articles
The Global Insight
Black swans, frankenfirms, and the next Covid-19
Covid-19 was the low-probability, high-risk event that many companies and business leaders were not prepared to handle. Join Charles Hecker and a panel of Control Risks experts as they explore how agility in the face of unpredictable risk is key to building a resilient organization.
CFIUS And A Tale Of Two Internets
Deal makers must be cognizant of which countries are falling in line with the digital protectionism and disengagements of the US-China tech race, and to what extent.
Analysis
Navalny poisoning raises prospect of new sanctions on Russia
Following the poisoning of Russian opposition leader Alexei Navalny, Russia faces the prospect of new Western sanctions – a possibility heightened by post-election unrest in Belarus and US government reports of Russian interference in the upcoming US presidential election.
Analysis
The Invisible Risks of CFIUS: Timing and Uncertainty
An investor’s best approach in closing a deal in the US is to aggressively negotiate potential mitigation steps early in the transaction cycle.